Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $69.17 Consensus Target Price from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $70.50.

Several research firms have issued reports on ELVN. Stifel Nicolaus upped their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. HC Wainwright boosted their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Guggenheim initiated coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, The Goldman Sachs Group raised their price target on Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $52.81 on Tuesday. The company’s 50-day moving average is $45.26 and its 200-day moving average is $37.16. The firm has a market capitalization of $3.22 billion, a PE ratio of -31.62 and a beta of 0.24. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $54.88.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, analysts expect that Enliven Therapeutics will post -1.57 EPS for the current year.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. The trade was a 10.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 26,018 shares of company stock worth $1,113,888. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ELVN. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. increased its position in shares of Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares during the period. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV acquired a new position in Enliven Therapeutics in the first quarter valued at about $38,000. Finally, Swiss National Bank lifted its position in Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.